

[Drug Injury Watch: New Obesity Drug Qsymia / Qsiva Gets Gets Negative Opinion By European Medicines Agency \(EMA\)](#)

Combination Pill Of Topamax And Phentermine Was Approved By FDA, But EMA Points To Heart Side Effects, Birth Defects, And Other Safety Issues

(Posted by Tom Lamb at www.DrugInjuryWatch.com on October 22, 2012)

Summary: On October 18, 2012 European drug regulators took a different course than the FDA with regard to a new anti-obesity medication which contains the active ingredient in Topamax, topiramate, and phentermine.

As for the actual determination, we get the details from this European Medicines Agency document (PDF), "[Refusal of the marketing authorisation for Qsiva \(phentermine / topiramate\)](#)".

This new diet-drug pill is called Qsymia here in the US and Qsiva in Europe.

[\[Read article in full at original source\]](#)

Earlier articles by attorney Tom Lamb on the Drug Injury Watch blog:

- [Intramedullary Nailing Surgery Is Successful Treatment For Patients With Femur Fractures From Use Of Fosamax Or Other Bisphosphonates](#)
- [Tekturna And Other Aliskiren Related Blood Pressure Medications Can Cause Renal Failure, Kidney Complications, And Strokes](#)
- [Disturbing Information About NuvaRing Safety Found In Motions On Experts Recently Unsealed By Federal Court MDL Judge](#)
- [Fall 2012: Two Recent Medical Reports Regarding Safety Of Pradaxa, Boehringer Ingelheim's Anticoagulation Drug](#)
- [Subtrochanteric Femoral Fractures With Use Of Oral Bisphosphonates: Fosamax, Actonel, And Boniva](#)

Attorney [Tom Lamb](#) represents people in personal injury and wrongful death cases involving unsafe prescription drugs or medication errors. The above article was posted originally on his blog, **Drug Injury Watch** – with live links and readers' Comments.

<http://www.DrugInjuryWatch.com>